ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2463
0,01%
Bitcoin
67.724,63
0,36%
Brent Oil
81,295
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Covalent (CVGR)

  7. Covalent (CVGR) Notícias

CVGR

Covalent (CVGR)

Covalent
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CVGR
DataHoraFonteTítuloCódigoCompanhia
30/10/200613:34Business WireCovalent Group Changes Name to Encorium Group, Inc.NASDAQ:CVGRCovalent
20/10/200617:08Business WireCovalent Group, Inc. Announces Results of Shareholder VoteNASDAQ:CVGRCovalent
19/10/200609:01Business WireCovalent Signs $8.2 Million in Contracts For Multinational Studies to Treat InfluenzaNASDAQ:CVGRCovalent
08/08/200617:36Business WireCovalent Reports 2006 Second Quarter Financial Results; Company to Hold Conference Call at 9:00 AM on Wednesday, August 9, 2006NASDAQ:CVGRCovalent
07/08/200609:24Business WireCovalent Group, Inc. Announces $1.7 Million Contract For Phase 2 Clinical Trial in AtherosclerosisNASDAQ:CVGRCovalent
02/08/200611:14Business WireCovalent Group, Inc. Schedules Second Quarter Financial Results and Conference CallNASDAQ:CVGRCovalent
13/07/200613:00Business WireCovalent Group, Inc. Signs Contracts Totaling $1.5 Million for Clinical Studies Offering Advanced Therapeutic Approaches to PatNASDAQ:CVGRCovalent
06/07/200615:15Business WireCovalent Group Amends Business Combination Agreement with Remedium OyNASDAQ:CVGRCovalent
28/06/200609:27Business WireCovalent Group, Inc. Announces $2.1 Million of New Business Contracts; Reiterates Second Quarter GuidanceNASDAQ:CVGRCovalent
15/05/200618:22Business WireCovalent Reports 2006 First Quarter Financial Results and Summary Balance Sheet Data; Company to Hold Conference Call at 9:00 ANASDAQ:CVGRCovalent
08/05/200609:12Business WireCovalent Group, Inc. Schedules First Quarter Financial Results and Conference CallNASDAQ:CVGRCovalent
20/04/200609:07Business WireCovalent Group, Inc. Signs $1 Million Contract To Conduct Phase 1 Study of Drug to Prevent/Treat Infectious DiseaseNASDAQ:CVGRCovalent
30/03/200610:00Business WireCovalent Group, Inc. Announces Additional New Business ContractsNASDAQ:CVGRCovalent
21/03/200619:15Business WireCovalent Group, Inc. Announces $2.1 Million Contract To Conduct Patient Disease Registry In Hospitalized Subjects With HyponatrNASDAQ:CVGRCovalent
21/03/200619:14Business WireCovalent Group, Inc. Signs $1.3 Million in Consulting and Medical Writing Contracts to Support New Drug Applications (NDA) forNASDAQ:CVGRCovalent
21/03/200619:12Business WireCovalent Reports 2005 Fourth Quarter and Year End Financial Results and Summary Balance Sheet Data; Company to Hold ConferenceNASDAQ:CVGRCovalent
16/03/200609:57Business WireCovalent Group, Inc. Schedules Fourth Quarter Financial Results and Conference CallNASDAQ:CVGRCovalent
03/03/200610:12Business WireCovalent Group, Inc. Enters into Combination Agreement with Remedium Oy; Conference Call Scheduled for 11:00 AM ET TodayNASDAQ:CVGRCovalent
08/02/200612:31Business WireCovalent Group, Inc. and Sudler & Hennessey Announce Strategic Partnership to Design and Conduct Global Patient Disease RegistriNASDAQ:CVGRCovalent
02/02/200611:01Business WireCovalent Group, Inc. Signs $2.2 Million Contract With New Sponsor to Conduct Clinical Trial in Patients with Cardiovascular DiseNASDAQ:CVGRCovalent
31/01/200615:00Business WireCovalent Group, Inc. Retains The Equity Group to Provide Investor Relations ServicesNASDAQ:CVGRCovalent
24/01/200611:00PR Newswire (US)Covalent Group, Inc. Announces Multiple New Business Contracts with an Aggregate Value of $1.0 MillionNASDAQ:CVGRCovalent
18/01/200611:00PR Newswire (US)Covalent Group, Inc. Signs Contract for $2.3 Million to Conduct a Multinational Phase 2 Clinical Trial Involving a New AntithromNASDAQ:CVGRCovalent
08/12/200510:00PR Newswire (US)Covalent Group, Inc. Signs Letter-of-Intent to Conduct $2.2 Million Multinational Phase 2 Clinical Trial in Cardiovascular DiseaNASDAQ:CVGRCovalent
05/12/200510:01PR Newswire (US)Covalent Group, Inc. and Emergent BioSolutions Sign Contract to Develop Immune Globulins for Treatment Exposure of Anthrax InfecNASDAQ:CVGRCovalent
18/11/200512:30PR Newswire (US)CSC's DVC Reaches Milestone in Plague Vaccine Clinical TrialNASDAQ:CVGRCovalent
11/11/200513:20PR Newswire (US)/C O R R E C T I O N -- Covalent Group, Inc. /NASDAQ:CVGRCovalent
10/11/200520:01PR Newswire (US)Covalent Reports Results for Third Quarter 2005NASDAQ:CVGRCovalent
07/11/200511:03PR Newswire (US)Covalent Group, Inc. to Report Third Quarter 2005 Results on Thursday, November 10NASDAQ:CVGRCovalent
06/10/200510:01PR Newswire (US)Covalent Group, Inc. Announces $5.3 Million Contract to Provide Additional Services for a Global Phase 3 Trial in HypertensionNASDAQ:CVGRCovalent
 Apresentando as notícias mais relevantes sobre:NASDAQ:CVGR

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
CIEL3
CIELO ON
BOV
PRIO3
PETRORIO ON
BOV
TELB4
TELEBRAS PN
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
OIBR3
OI ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
VVEO3
CM Hospitalar ON
BOV
BLAU3
Blau Farmaceutica ON
BOV
TPIS3
TRIUNFO PART ON
BOV
SGPS3
SPRINGS ON
BOV
PETR4
PETROBRAS PN
BOV
IDIV
Dividend
BOV
TECN3
TECHNOS ON
BOV
COGN3
COGNA ON
BOV
RCSL3
RECRUSUL ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados